Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amiot

Showing results (721-730 of 823) with videos related to

Pageof 83
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Gastroenterology|November 19, 2008
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type IIGeorgia Malamut, Pauline Afchain, Virginie Verkarre, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2017
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained RemissionCatherine Reenaers, Jean-Yves Mary, Maria Nachury, et al.
The American Journal of Gastroenterology|June 24, 2025
Fruits, vegetables, legumes and potatoes and risk of Crohn's disease and ulcerative colitisAntoine Meyer, Franck Carbonnel, Christina C Dahm, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort studyAurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort studyMathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Journal of Crohn'S & Colitis|January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort StudyAntoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Nucleic Acids Research|July 21, 2006
An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomesKévin Le Brigand, Roslin Russell, Chimène Moreilhon, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 28, 2025
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT StudyAhmad Albshesh, Piotr Kucha, Daniela Pugliese, et al.
Blood|December 14, 2023
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimeticsRomane Durand, Géraldine Descamps, Céline Bellanger, et al.
Pageof 83

Showing results (721-730 of 823) with videos related to

Sort By:
Pageof 83
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Gastroenterology|November 19, 2008
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type IIGeorgia Malamut, Pauline Afchain, Virginie Verkarre, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2017
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained RemissionCatherine Reenaers, Jean-Yves Mary, Maria Nachury, et al.
The American Journal of Gastroenterology|June 24, 2025
Fruits, vegetables, legumes and potatoes and risk of Crohn's disease and ulcerative colitisAntoine Meyer, Franck Carbonnel, Christina C Dahm, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort studyAurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort studyMathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Journal of Crohn'S & Colitis|January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort StudyAntoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Nucleic Acids Research|July 21, 2006
An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomesKévin Le Brigand, Roslin Russell, Chimène Moreilhon, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 28, 2025
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT StudyAhmad Albshesh, Piotr Kucha, Daniela Pugliese, et al.
Blood|December 14, 2023
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimeticsRomane Durand, Géraldine Descamps, Céline Bellanger, et al.
Pageof 83